Last --
Change Today 0.00 / 0.00%
Volume 0.0
All times are local (Market data is delayed by at least 15 minutes).

ambrx inc (AMBX) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
17.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMBRX INC (AMBX)

Related News

No related news articles were found.

ambrx inc (AMBX) Related Businessweek News

No Related Businessweek News Found

ambrx inc (AMBX) Details

Ambrx, Inc. discovers and develops protein therapeutics. The company develops a pipeline of product candidates that include antibody drug conjugates (ADCs), bi- and multi-specific drug conjugates, and long-acting therapeutic proteins. Its ADCs comprise ARX788, a human epidermal growth factor 2 (HER2) antibody, which is in preclinical development for the treatment of breast cancer and other solid tumors that express and overexpress HER2. The company’s long-acting proteins consist of ARX201, a human growth hormone, which has completed a Phase IIb clinical trial in young adults with growth hormone deficiency; and ARX328, which is in preclinical development as a leptin-replacement therapy in patients with lipodystrophy and weight management. Its other ADC and bi-specific product candidates include PSMA ADC for the treatment of metastatic castration-resistant prostate cancer and glioblastoma multiforme; CD70 ADC for the treatment of renal and nasopharyngeal cancers; Bi-specific Anti-CD3 X Folate for the treatment of ovarian cancer; and CD184-FK506 ADC for the treatment of immunological diseases. The company has collaborations with Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Eli Lilly and Company, Agensys, Inc., Zhejiang Medicine Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. Ambrx, Inc. was founded in 2003 and is based in La Jolla, California.

74 Employees
Last Reported Date: 06/9/14
Founded in 2003

ambrx inc (AMBX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Co Founder and Senior Advisor
Total Annual Compensation: --
Principal Financial & Accounting Officer and ...
Total Annual Compensation: --
Chief Business Officer
Total Annual Compensation: --
Vice President of Intellectual Property
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

ambrx inc (AMBX) Key Developments

Ambrx Seeks Acquisitions

Ambrx, Inc. has filed an IPO in the amount of $86.25 million. Ambrx may use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products. However, Ambrx has no current commitments or obligations to do so.

Ambrx, Inc. and Zhejiang Hisun Pharmaceutical Co., Ltd. to Collaborate on the Development and Commercialization of Bispecifics for Cancer

Ambrx Inc. and Zhejiang Hisun Pharmaceutical Company Ltd. announced a collaboration for the development and commercialization of bispecifics based on Ambrx technology for the treatment of cancer. Hisun will have commercial rights to the products in China, while Ambrx will retain commercial rights outside of China and will be entitled to receive royalties on sales of the products in China. Hisun will manufacture the product to cGMP standards for clinical and commercial supplies on a global basis.

Sheila Gujrathi Joins Ambrx Board of Directors

Ambrx Inc. announced that Sheila Gujrathi, M.D., has joined its board of directors. Dr. Gujrathi is currently the chief medical officer at Receptos, where she is responsible for the clinical development of therapeutic candidates for the treatment of immune and metabolic diseases.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMBX:US $0.00 USD 0.00

AMBX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMBX.
View Industry Companies
 

Industry Analysis

AMBX

Industry Average

Valuation AMBX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMBRX INC, please visit www.ambrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.